Please login to the form below

Not currently logged in
Email:
Password:

BioMarin licenses cystic fibrosis technology from UCSF

US-headquartered BioMarin Pharmaceutical has licensed from the University of California, San Francisco (UCSF) intellectual property covering compounds demonstrated to improve cystic fibrosis transmembrane conductance regulator (CFTR) protein functionality.

US-headquartered BioMarin Pharmaceutical has licensed from the University of California, San Francisco (UCSF) intellectual property covering compounds demonstrated to improve cystic fibrosis transmembrane conductance regulator (CFTR) protein functionality.

BioMarin expects the lead compounds to undergo additional animal testing and optimisation, with an expected IND filing for 2009.

CFTR is a transmembrane protein that functions primarily as a chloride channel in the plasma membrane of epithelial cells. The most common mutation in cystic fibrosis (CF) causes deformity to specific protein, which leads to a build up of mucous and severe infections in the lungs.

Jean-Jacques Bienaime, BioMarin's CEO, said: "We are pleased to add this programme to our growing product development pipeline. The cystic fibrosis indication aligns well with our existing product portfolio and core competencies, as it is a well-defined and relatively large orphan disease. It has a clear clinical and regulatory path and will allow us to leverage our commercial infrastructure targeting specialists."

CF affects an estimated 30,000 patients in the US and around 40,000 patients outside the US. The median age of survival of a CF patient is 36.5 years. Datamonitor identified 15 ongoing CF-related projects most of which were in phase II clinical trials.

24th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics